Profile
Kelly Michael Aaron is a corporate director whose profile appears in SEC filings as a director for multiple public companies as of May 14, 2026. Specifically, he is listed as a director for DMC Global Inc., Amicus Therapeutics, Inc., Prime Medicine, Inc., and Neogenomics Inc. While additional biographical details such as education or prior executive roles are not disclosed in the provided SEC context, the repeated board-level roles across diverse, publicly traded firms suggest governance experience, strategic oversight, and fiduciary responsibilities typical of a non-employee director.
| Role | Director |
|---|
| Notability | 60/100 |
|---|
Board memberships
- DMC Global Inc.
- Amicus Therapeutics, Inc.
- Prime Medicine, Inc.
- Neogenomics Inc.
Awards & honors
- Serves as a director for four public companies as of 2026
- Governance and fiduciary oversight at multiple boards
Frequently Asked Questions
Who is Kelly Michael Aaron?
Kelly Michael Aaron is a corporate director whose profile appears in SEC filings as a director for multiple public companies as of May 14, 2026. Specifically, he is listed as a director for DMC Global Inc., Amicus Therapeutics, Inc., Prime Medicine, Inc., and Neogenomics Inc. While additional biographical details such as education or prior executive roles are not disclosed in t…
How many SEC Form 4 filings has Kelly Michael Aaron submitted recently?
4 primary Form 4 filings in the last 90 days, covering 4 companies.
Has Kelly Michael Aaron been buying or selling stock?
Recorded transactions: 1 open-market purchases ($38K) and 0 open-market sales () across all tracked filings.
Where can I see all of Kelly Michael Aaron's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.